22 active
/
49 total (since 2015)
2
Phase 1 Active
8 total
10
Phase 2 Active
24 total
9
Phase 3 Active
17 total
5
Phase 4 Active
7 total
Top Sponsors (Industry)
Sorted by active Active Done Failed
Shandong Suncadia Medicine Co., Ltd. 4 3 0
Cytokinetics 3 4 0
Bristol-Myers Squibb 1 2 0
Imbria Pharmaceuticals, Inc. 1 1 0
Lexicon Pharmaceuticals 1 0 0
Edgewise Therapeutics, Inc. 1 0 0
Bayer 1 0 0
Tenaya Therapeutics 1 0 0
NCT05182658 ACTIVE NOT RECRUITING
Empagliflozin in Hypertrophic Cardiomyopathy
National Institute of Cardiology, Warsaw, Poland n=250
NCT06481891 RECRUITING
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
Lexicon Pharmaceuticals n=500
NCT07023341 ACTIVE NOT RECRUITING
A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Bayer n=36
NCT06412666 RECRUITING
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
Cytokinetics n=55
NCT06081894 ACTIVE NOT RECRUITING
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
Cytokinetics n=500
NCT04848506 ENROLLING BY INVITATION
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
Cytokinetics n=900
NCT07202897 NOT YET RECRUITING
LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
Rennes University Hospital n=532
NCT07021976 RECRUITING
A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
Shandong Suncadia Medicine Co., Ltd. n=216
NCT06873828 NOT YET RECRUITING
Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring
Yonsei University n=100
NCT05186818 COMPLETED
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
Cytokinetics n=282
NCT03723655 COMPLETED
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
Bristol-Myers Squibb n=314
NCT06116968 COMPLETED
An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
Corxel Pharmaceuticals n=40
NCT05767346 COMPLETED
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
Cytokinetics n=175
NCT05174416 COMPLETED
A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
LianBio LLC n=81
NCT05366101 COMPLETED
Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy
Newcastle-upon-Tyne Hospitals NHS Trust n=168
NCT03470545 COMPLETED
Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
MyoKardia, Inc. n=251
NCT02291237 TERMINATED
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Gilead Sciences n=172
Data: ClinicalTrials.gov